Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

Plethora Solutions welcomes Jamie Gibson as new CEO

By Giles Gwinnett

December 20 2013, 3:51pm
He has spent most of his professional career working with Plethora chairman Jim Mellon at Regent Pacific Group specialising in corporate finance and direct equity investments



Jamie Gibson has been appointed the new chief executive at Plethora Solutions (LON:PLE) starting January 1.

Gibson, 47, is tasked with driving the commercialisation of the firm's treatment for premature ejaculation PSD502 and leading initiatives on manufacturing strategy.

He has spent most of his professional career working with Plethora chairman Jim Mellon at Regent Pacific Group specialising in corporate finance and direct equity investments.

Mellon said: "We welcome Jamie whom I have worked with at Regent Pacific for over 17 years; we wish him every success in his new role.

"We are extremely pleased to have such an experienced team lead our business development activities, which is part of the company's disciplined approach to increasing shareholder value through the successful commercialisation of PSD502."

Reading Shares - For a company Plethora's size the potential of its product is a crucial factor for investors when deciding to back the stock. The company has an offering larger companies would pay to own in their search to replace lost income.

Company update

RNS


RNS Number : 9983B

Plethora Solutions Holdings PLC

11 March 2014










11 March 2014



Plethora Solutions Holdings PLC

("Plethora" or the "Company")

Company update



Plethora (AIM: PLE) is pleased to inform shareholders that our recent meeting during Q1 2014 with the United States Food and Drug Administration ("FDA") has now unambiguously defined the path to a successful submission of the New Drug Application for PSD 502. Appropriate actions are well underway with the Company's various consultants. Importantly, the FDA has confirmed that premature ejaculation is an area of high medical need with a requirement for effective therapy and recognises the importance of the initiatives that Plethora has made towards this goal.

The Company sees a significant potential market opportunity for PSD 502 both in the United States and EU. Based on the Company's internal modeling and pricing input from its US marketing consultant, the Company forecasts in excess of US$1 billion per annum peak prescription sales. It therefore sees significant value in PSD 502 for the Company's shareholders and correspondingly, management is to looking to unlock that value as quickly as possible through bringing to closure negotiations with potential marketing partners. In this respect, the Company has received several expressions of interest for out-licensing PSD 502 in the US, EU and other territories. Negotiations are at a more advanced stage with a number of potential marketing partners and the Company is hopeful that an announcement will be made in this regard over the coming months. However, shareholders should please note that given the nature of licensing talks, it is not possible to determine with accuracy the timing of completing such agreements, nor to give guidance on the terms thereof.

The Company is also making excellent progress with its preferred manufacturing partner and is hopeful that an announcement will be made within the next month.

Plethora Solutions eyeing US$1bn a year in sales

By Giles Gwinnett

March 11 2014, 8:46am
The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant, mean it now forecasts more than US$1 billion per annum peak prescription sales
The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant, mean it now forecasts more than US$1 billion per annum peak prescription sales


Plethora Solutions (LON:PLE) shares raced up Tuesday as it reported positive progress in the USA for its lead product, PSD 502 for premature ejaculation.

The firm's recent meeting with the United States Food and Drug Administration (FDA) has now "unambiguously defined the path" to a successful submission for making a drug application for 502, said the company, which now forecasts more than US$1 billion per annum peak prescription sales.

Investors hailed the brief statement, sending shares up over 22% to 11 pence each.

The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant means it now forecasts more than US$1 billion per annum peak prescription sales.

The firm said it's looking to unlock value as quickly as possible through bringing to closure negotiations with potential marketing partners for PSD 502.

"In this respect, the company has received several expressions of interest for out-licensing PSD 502 in the US, EU and other territories," it said.

Negotiations are at a more advanced stage with a number of potential marketing partners and Plethora said it was hopeful that an announcement will be made over the coming months.

"The company is also making excellent progress with its preferred manufacturing partner and is hopeful that an announcement will be made within the next month."
--------------------------------------------------------------------------------------------

UPDATE - Plethora Solutions eyeing US$1bn a year in sales

By Giles Gwinnett

March 11 2014, 5:46pm
The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant, mean it now forecasts more than US$1 billion per annum peak prescription sales
The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant, mean it now forecasts more than US$1 billion per annum peak prescription sales


--ADDS BROKER COMMENT--

Plethora Solutions (LON:PLE) shares soared on Tuesday as it reported positive progress in the USA for its lead product for premature ejaculation.

The firm's recent meeting with the United States Food and Drug Administration (FDA) has now "unambiguously defined the path" to a successful submission for making a drug application for PSD 502.

The AIM-listed company saw its shares jump 24% to 11.1p on the news.

The US is the world's biggest drug market and Plethora's internal modelling and input from its US marketing consultant means it now forecasts more than US$1 billion a year in peak prescription sales.

The firm said it is looking to unlock value as quickly as possible by bringing to a close negotiations with potential marketing partners for PSD 502.

“In this respect, the company has received several expressions of interest for out-licensing PSD 502 in the US, EU and other territories,” it said.

Negotiations are at a more advanced stage with a number of potential marketing partners.

“The company is also making excellent progress with its preferred manufacturing partner and is hopeful that an announcement will be made within the next month,” it added.

The shares have put on 550% since trading at just 2p a year ago amid funding issues.

Daniel Stewart lifted its target price on the stock from 18.9p to 25.6p on Tuesday, reducing its discount rate from 19% to 15% in its DCF (discounted cash flow) model now that the treatment is closer to being awarded US approval.

“We continue to see significant scope for reducing our conservative discount rate, and hence increasing our target price, as PSD502 further progresses through to US approval and commercial launch,” analyst Vadim Alexandre said.

Plethora Solutions: Daniel Stewart moves shifts target price from 18.9p to 25.6p and keeps a buy recommendation.

Another 10% today

UPDATE - Plethora Solutions secures manufacturing development partner for PSD502

By Giles Gwinnett

March 26 2014, 3:30pm
PSNW will generate data to vary the EU licence variation and complete work for the initial submission of the New Drug Application (NDA) with the United States Food and Drug Administration (FDA)
PSNW will generate data to vary the EU licence variation and complete work for the initial submission of the New Drug Application (NDA) with the United States Food and Drug Administration (FDA)


---ADDS BROKER COMMENT AND SHARE PRICE---

Plethora Solutions (LON:PLE) reached a further milestone in its commercialisation of its lead product - by securing a supply chain and manufacturing development partner.

Pharmaserve North West Limited (PSNW) will carry out the manufacturing for the new six dose canister of PSD502 for premature ejaculation.

PSNW will generate data to vary the EU licence variation and complete work for the initial submission of the New Drug Application (NDA) with the United States Food and Drug Administration (FDA).

Plethora reckons it will spend around £1mln on the manufacturing, including the supply of raw materials, to the end of 2014.

Chairman Jim Mellon told investors: "We welcome Pharmaserve as our manufacturing partner for developing the six dose canister and more importantly providing commercial supplies of PSD502 for the EU market and other territories.

"This is an extremely important milestone for the company in its ability to provide commercial supplies to its potential marketing partners in our efforts to commercialise PSD502. In this respect, our efforts continue at pace in securing marketing partners for PSD502."

PSNW is a leading manufacturing organisation, which specialises in the development and manufacture of metered dose inhalers (MDI's), dry powder inhalers (DPI's) and other pharmaceutical aerosols.

Following the announcement, house broker Daniel Stewart gave a 'buy' rating on the shares and repeated its target price of 25.6p.

On Wednesday, Plethora shares eased 0.94% to stand at 13.125p.

A good recovery rise of 17%

Stick with it folks!... and top up when you can! (imho & dyor)

Tally bally ho Huzzah and hoooorahhhhh!!

onwards and upwards north of 10p today

great news ;